MapLight Therapeutics is a clinical-stage biopharmaceutical company developing oral medicines for central nervous system disorders. Its pipeline includes candidates for schizophrenia and Alzheimer’s disease psychosis (such as an M1/M4 muscarinic agonist) and for autism spectrum disorder. With little or no product revenue, the company focuses on advancing mid-stage clinical trials rather than commercial sales.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q4 2024 | 0 | — | — | — |
| Q3 2025 | 0 | — | -29.4 | — |
| Q4 2025 | 0 | — | -79.5 | — |
| Q1 2026 | 0 | — | -60.7 | — |
| Q2 2026 | 0 | — | -60.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Bank of Marin Bancorp (BMRC), TAT Technologies Ltd. (TATT), Gladstone Capital Corporation (GLAD), Monro, Inc. (MNRO), Autolus Therapeutics plc (AUTL), Pioneer Bancorp, Inc. (PBFS)